Keyphrases
Active Disease
14%
Adult Patients
14%
Aminosalicylates
14%
Assessment Criteria
7%
Bleeding Score
14%
Clinical Remission
7%
Clinical Response
7%
Clinical Trial Design
7%
Clinical Trials
14%
Cochrane
7%
Conference Proceedings
7%
Confidence Interval
100%
Corticosteroids
14%
Cumulative Meta-analysis
14%
Demographic History
7%
Design Features
7%
Disease Activity Score
21%
Disease Duration
21%
Disease Severity
7%
Drug Class
7%
Embase
7%
Endoscopy
21%
Endpoint Assessment
7%
Enrollment Criteria
7%
Event Rate
7%
Extracted Data
7%
Funnel Plot
7%
Gastroenterology
7%
History of Disease
7%
Induction Period
7%
Induction Therapy
100%
Level Characteristic Values
7%
Logit
7%
Maintenance Phase
7%
Maintenance Studies
7%
Maintenance Therapy
100%
Mayo Clinic Score
7%
MEDLINE
7%
Meta-analysis
7%
Meta-regression
7%
Methodological Quality
7%
Mixed Effects
7%
New Trial
7%
Outcome Assessment
14%
Participant Demographics
7%
Placebo
92%
Placebo Response
14%
Placebo Response Rate
100%
Placebo-controlled
7%
Point Estimate
7%
Publication Bias
7%
Randomized Controlled Trial
21%
Randomized Trial
100%
Rectal Bleeding
21%
Regression Analysis
7%
Remission
28%
Remission Induction
7%
Remission Rate
100%
Required Sample Size
7%
Response Rate
7%
Risk of Bias Tool
7%
Screening Process
7%
Search Methods
7%
Selection Criteria
7%
Systematic Meta-analysis
7%
Treatment Difference
7%
Trial Characteristics
7%
Trial Design
7%
Trial Duration
7%
Trial Eligibility
7%
Ulcerative Colitis
100%
Ulcerative Colitis Therapy
7%
Medicine and Dentistry
Biological Product
14%
Clinical Trial
14%
Clinical Trial Design
7%
Disease Activity
21%
Disease Duration
21%
Disease Severity
7%
Diseases
21%
Endoscopy
21%
Funnel Plot
7%
Gastroenterology
7%
Immunosuppressive Drug
7%
Maintenance Therapy
100%
Meta-Analysis
21%
Meta-Regression
14%
Outcome Assessment
14%
Patient with Ulcerative Colitis
7%
Placebo
100%
Placebo Effect
100%
Randomized Controlled Trial
21%
Rectal Bleeding
21%
Spontaneous Remission
100%
Systematic Review
7%
Ulcerative Colitis
100%
Nursing and Health Professions
Biological Product
7%
Confidence Interval
53%
Disease
11%
Disease Activity
11%
Disease Duration
11%
Disease Severity
3%
Endoscopy
11%
Hospital
3%
Immunosuppressive Agent
3%
Maintenance Therapy
100%
Meta Analysis
11%
Outcome Assessment
7%
Outcome Variable
3%
Patient with Ulcerative Colitis
3%
Placebo
100%
Rectum Hemorrhage
11%
Remission
100%
Sample Size
3%
Systematic Review
3%
Ulcerative Colitis
100%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
7%
Clinical Trial
7%
Clinical Trial Design
3%
Disease
11%
Disease Activity
11%
Disease Duration
11%
Disease Severity
3%
Gastroenterology
3%
Immunosuppressive Agent
3%
Placebo
100%
Randomized Controlled Trial
11%
Rectum Hemorrhage
11%
Remission
100%
Ulcerative Colitis
100%